Skip to main content
. 2022 Nov 10;86:104321. doi: 10.1016/j.ebiom.2022.104321

Fig. 5.

Fig. 5

B-cell kinetics in the first dosing interval of inebilizumab predict long-term deep B-cell depletion. (a) Profile plot of CD20+ B-cell counts in individual patients throughout the first dosing interval with inebilizumab. (b) Total CD20+ B-cell counts over 3 years of inebilizumab treatment in patients with B-cell counts >4 cells/μL and ≤4 cells/μL at the end of the first dosing period. Points show medians ± IQR. Mann–Whitney U test was used to calculate p values. IQR = interquartile range, LLOQ = lower limit of quantification.